ArticleClinical epidemiology2025
Risk of Second Primary Cancer Among Patients with Thyroid Carcinoma in Finland: A Nationwide Population-Based Study.
Article in Clinical epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Thyroid cancer (TC) survivors face an increased risk of second primary cancers (SPCs). While previous research on the risk of SPCs among TC patients has been conducted in other regions, comprehensive data from Northern Europe remain limited. Our register-based cohort study aimed to evaluate the risk of SPCs among Finnish TC survivors. Patients and Methods: We obtained data on all patients diagnosed with TC in Finland in 1953-2022 from the Finnish Cancer Registry (FCR). Standardized incidence ratios (SIRs) of SPCs were calculated relative to the risk of cancer in the general population. Results: We identified 14,520 patients with TC (3,212 males, 22%; 11,308 females, 78%), with a median follow-up of 12.1 years. A metachronous SPC was diagnosed in 16.4% (n=527) of males and 15.5% (n=1,744) of females. The overall SPC risk was elevated for both males (SIR 1.23, 95% CI 1.12-1.34; EAR 2.39/1,000 PYs) and females (1.24, 1.19-1.30; EAR 1.92/1,000 PYs). Female patients with papillary TC (PTC) displayed increased SIRs for breast (SIR 1.26, 95% CI:1.15-1.37), urinary organ (1.50, 1.19-1.86), brain (1.85, 1.48-2.29), and hematolymphoid cancers (1.31, 1.10-1.54). Males with PTC showed an increased risk of urinary organ (SIR 1.39, 1.01-1.85), brain (2.73, 1.69-4.17), and hematolymphoid cancers (1.52, 1.12-2.01). The elevated SPC risk of the breast and brain persisted even after 20 years of follow-up. An increased incidence of SPCs of the urinary organs, brain, and hematolymphoid tissues was observed in females diagnosed with follicular TC (FTC) or medullary TC (MTC) in 1953-1985. Conclusion: Our results indicate an excess risk of cancers of the breast, urinary organs, brain and hematolymphoid tissues for Finnish patients with a history of PTC. For FTC and MTC risk of cancers of the urinary organs, brain, and hematolymphoid tissues is specific for female patients diagnosed in 1953-1985.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.